Clinical Trial Update: A Clinical Trial Evaluating TG4050 in Head and Neck Cancer [Phase 1, Phase 2]

View source ↗

Summary

The update describes Transgene's TG4050 in a Phase 1/2 trial for Squamous Cell Carcinoma of Head and Neck, with the study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of Head and Neck

Drugs mentioned

• TG4050

Snippet

Sponsor: Transgene | Conditions: Squamous Cell Carcinoma of Head and Neck | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING